SLC5A2 and heart failure: With a generally favorable safety profile in nondiabetic populations and strong Class I guideline recommendations in heart failure with reduced ejection fraction, SGLT2 inhibitors are now recognized as one of the four core pillars of guideline-directed medical therapy.